Ectodomain cleavage of the ErbB-4 receptor tyrosine kinase generates a membrane-associated fragment of 80 kDa (m80) that has been subjected to N-terminal sequencing. The sequence obtained shows that the N terminus of this fragment begins with Ser-652 of ErbB-4. When a 12-residue peptide corresponding to ErbB-4 residues 646 -657 was incubated with recombinant tumor necrosis factor-␣-converting enzyme, fragments representing residues 646 -651 and 652-657 were obtained. These data indicate that ectodomain cleavage of ErbB-4 occurs between His-651 and Ser-652, placing the cleavage site within the ectodomain stalk region approximately 8 residues prior to the transmembrane domain. Several experiments have characterized other aspects of the m80 ErbB-4 fragment. Inhibition of ErbB-4 tyrosine kinase activity with pan-ErbB tyrosine kinase inhibitors indicates that kinase activity is stringently required for heregulindependent, but not 12-O-tetradecanoylphorbol-13-acetate-induced, ErbB-4 ectodomain cleavage and formation of the m80 fragment. When the m80 ErbB-4 fragment is generated by cell treatment with heregulin or 12-O-tetradecanoylphorbol-13-acetate, the fragment associates with intact ErbB-2. However, this fragment does not associate with the intact ErbB-4 molecule.
ErbB-4 is a member of the ErbB receptor tyrosine kinase family, which also includes the epidermal growth factor receptor (ErbB-1), ErbB-2, and ErbB-3 (1). ErbB-4 and ErbB-3 bind the neuregulin (heregulin) family of growth factors, and ErbB-4 also recognizes certain growth factors in the epidermal growth factor family of ErbB-1 agonists, such as betacellulin, epiregulin, and heparin-binding epidermal growth factor. ErbB-4 heterodimerizes with ErbB-2 as do ErbB-1 and ErbB-3; however, ErbB-4 can also signal through the formation of ErbB-4 homodimers.
Within the receptor tyrosine kinase family, ErbB-4 is uniquely processed (2) by a proteolytic pathway that is known to occur with certain other transmembrane proteins, such as Notch (3), the low density lipoprotein receptor-related protein (4), the amyloid precursor protein (APP) 1 (5) , and the adhesion molecules CD44 (6, 7) and E-cadherin (9) . The first step in this pathway involves the release of the ErbB-4 ectodomain by a cleavage that produces two fragments as follows: a 120-kDa ectodomain fragment and an 80-kDa membrane-associated fragment, designated m80 (9) . The latter fragment contains the ErbB-4 transmembrane domain and the entire cytoplasmic region, including the tyrosine kinase domain. Ectodomain cleavage of ErbB-4 in cells occurs at a low constitutive or basal level (10) that can be increased by TPA (9) or by heregulin or other growth factors that bind ErbB-4 (11) . Also, cleavage is potentiated by the addition to cells of pervanadate, a tyrosine phosphatase inhibitor that provokes ErbB-4 tyrosine phosphorylation (12) . The ectodomain cleavage of ErbB-4 is sensitive to metalloprotease inhibitors (10) and does not occur in cells genetically deficient in tumor necrosis factor-␣-converting enzyme (TACE), a transmembrane metalloprotease, also known as a disintegrin and metalloprotease or ADAM17 (13) . The mechanism by which TACE participates in this cleavage is not understood. Interestingly, a splice form of ErbB-4 known as Jm-b is present in human and mouse tissues and is resistant to ectodomain cleavage (14) . Compared with the cleavable Jm-a isoform of ErbB-4, the Jm-b isoform contains a unique sequence within the ectodomain stalk region.
The ErbB-4 m80 fragment that is generated by ectodomain cleavage is further processed by two competing protease activities. The fragment can be degraded by proteosome activity following polyubiquitination (10) . More importantly, the m80 fragment is also a substrate for ␥-secretase activity (2, 15) . ␥-Secretase is a multicomponent proteolytic activity that cleaves proteins, such as Notch and APP, within their transmembrane domains and releases the cytoplasmic domains from the plasma membrane allowing them to relocalize within the cell (6) . In the case of ErbB-4, as well as Notch and APP, the cytoplasmic domain is rapidly found in the nucleus (2, 15) . Although the function of the ErbB-4 cytoplasmic domain in the nucleus is not known, evidence indicates that heregulin-dependent cell death in T47D cells requires ␥-secretase activity (2) .
The capacity of ErbB-4 to be processed by ␥-secretase activity requires ectodomain cleavage as a prerequisite (2) . This is analogous to the processing of Notch and APP (5) and is likely the point at which ErbB-4 processing is regulated by TPA or heregulin. Therefore, we have continued to investigate the ectodomain cleavage event and report herein several relevant findings.
EXPERIMENTAL PROCEDURES
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and PD153035 were purchased from Calbiochem-Novabiochem. CI-1003 was a gift from David Fry, Pfizer. Horseradish peroxidase-conjugated Protein A, Protein A-Sepharose, and Protein G-Sepharose were from Zymed Laboratories Inc. Dulbecco's modified Eagle's medium (DMEM) and fetal calf serum were from Invitrogen. Polyclonal antibody to residues 1291-1308 of the ErbB-4 C-terminal domain was obtained from Santa Cruz Biotechnology and was used for immunoprecipitation. Another polyclonal antibody to residues 1108 -1264 in the ErbB-4 Cterminal domain was a gift of Matthias Kraus, University of Alabama, Birmingham, and was used for Western blotting. A monoclonal antibody to the ectodomain of ErbB-4 was purchased from NeoMarkers, Inc. Anti-phosphotyrosine (monoclonal) was a product of Transduction Laboratories. Recombinant TACE catalytic domain (16) and the pro-TNF␣ peptide (Dnp-SPLAQAVRSSSR) were gifts of David Becherer, GlaxoSmithKline. The ErbB-4 peptide (Ac-YPWTGHSTLPQH) was a gift of James Tam, Vanderbilt University. Polyvinylidene difluoride (PVDF) membranes were from Bio-Rad. Anti-TACE, a purified monoclonal antibody to human TACE (M220), was generously provided by Roy Black, Immunex.
N-terminal Sequence Analysis-T47-14 cells were grown to confluence in 10 15-cm culture dishes and were then treated with TPA (100 ng/ml) for 45 min at 37°C. Subsequently, the cells were lysed in cold buffer (1% Nonidet P-40, 10 mM Tris, pH 7.4, 150 mM NaCl, 1 mM phenylmethylsulfonyl fluoride, aprotinin (10 g/ml), leupeptin (10 g/ ml)), and the lysate was clarified by centrifugation (14,000 ϫ g, 10 min). Polyclonal antibody (50 g) to the ErbB-4 C-terminal domain was then added and incubated for 2 h at 4°C before the addition of Protein A-Sepharose. After 2 h the resulting precipitate was washed in cold lysis buffer three times. The precipitate was then treated with a buffer containing 10 mM Tris-Cl, pH 7.4, 150 mM NaCl, and 1.5% SDS for 10 min at 100°C to elute precipitated proteins. The eluate was then diluted 10-fold into lysis buffer.
The diluted eluate was used for a second immunoprecipitation that employed a 2-h incubation with a monoclonal antibody to the ErbB-4 C-terminal domain and Protein G-Sepharose followed by washing with lysis buffer. This precipitate was placed on an SDS-PAGE, and after electrophoresis, the proteins were transferred to a PVDF membrane. The membrane was stained with Coomassie Blue, and a band at 80 kDa was cut out and eluted. Edman microsequencing using an Applied Biosystems 492 sequencer was performed by the Vanderbilt Peptide Sequencing and Amino Acid Analysis Shared Resource.
Analysis of Peptide Cleavage-Two synthetic 12-residue peptides were used as substrates: a pro-TNF␣ peptide that contains a dinitrophenyl group at the N terminus and that contains the known cleavage site present in the TNF␣ precursor, and an ErbB-4 peptide that is acetylated at the N terminus. Each peptide was incubated at 37°C for the indicated period of time in 20 mM Hepes buffer, pH 7.4, with or without the indicated concentration of recombinant human TACE catalytic domain (16) in a final volume of 50 l.
To assess cleavage of the peptide substrates by mass spectrometry, an aliquot (ϳ1 l) was mixed with 1 l of ␣-cyano-4-hydroxycinnamic acid (CHCA) matrix and spotted on a sample plate for mass spectrometry. This matrix was made using a saturated solution of ␣-cyano-4-hydroxycinnamic acid in 50:50 (v/v) mixture of acetonitrile and 0.1% trifluoroacetic acid in water. The samples were then assayed on a PerSeptive Biosystems Elite matrix-assisted laser desorption/ionization-time of flight-mass spectrometer utilizing the reflectron detector. Standardization of peptide masses was performed by utilizing a peptide mixture supplied by the Vanderbilt Mass Spectrometry Facility. Analysis was performed by the Vanderbilt Peptide Sequencing and Amino Acid Analysis Shared Resource.
Cell Culture-T47D cells are a human mammary carcinoma cell line obtained from the American Tissue Culture Collection. T47-14 cells are NIH/3T3 cells that have been transfected to express human ErbB-4 and were provided by Matthias Kraus, University of Alabama-Birmingham. Both have been described previously (9, 11) . The cells were grown in DMEM containing 10% fetal bovine serum and used for experiments when nearly confluent. Prior to each experiment the cells were incubated for about 24 h in DMEM plus 0.5% fetal bovine serum. Immediately prior to the addition of growth factors or TPA at 37°C, the cultures were washed with phosphate-buffered saline and DMEM containing 20 mM Hepes, pH 7.2, and 0.1% bovine serum albumin was added.
Cell Lysis and Immunologic Analysis-After each experimental treatment, the cells were washed with ice-cold phosphate-buffered saline and immediately lysed by the addition of cold TGH lysis buffer (1% Triton X-100, 10% glycerol, 20 mM Hepes, pH 7.2, 100 mM NaCl), supplemented with protease inhibitor mixture P8340 (Sigma) and 50 mM NaF, for 30 min at 4°C. The lysate was then centrifuged (14,000 ϫ g, 10 min) and the supernatant used for immunologic measurement and determination of protein concentration (Bio-Rad Protein Assay Reagent).
For subsequent immunoprecipitations ϳ1 mg of lysate was incubated with the indicated antibody for 30 min at 4°C with rocking followed by the addition of Protein A-or Protein G-Sepharose as appropriate, and the incubation was continued for 3 h at 4°C. The precipitates were then washed with TGH lysis buffer three times. Laemmli sample buffer (1.5ϫ) was then added, and the samples were heated (100°C) for 5 min. Subsequently the samples were vortexed and centrifuged (8,000 rpm, 2 min) to remove the Sepharose beads.
The samples were then loaded on SDS-PAGE (7.5%). After electrophoresis the separated proteins were transferred to Protran nitrocellulose membranes (Schleicher & Schuell). The membranes were blocked with 5% dry milk in TBST buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 0.05% Tween 20) for 1 h at room temperature with rocking. The membranes were then washed twice with TBST buffer and incubated overnight at 4°C with the indicated antibody in TBST buffer containing 1.0% bovine serum albumin. The membranes were then washed four times with TBST, and the horseradish peroxidase-conjugated Protein A was added for 1 h at room temperature with rocking. The samples were washed four times with TBST, and bound horseradish peroxidase was detected by enhanced chemiluminescence. Where indicated, blots were stripped and reprobed with a second antibody. The stripping solution contained 62.5 mM Tris-Cl, pH 6.7, 100 mM ␤-mercaptoethanol, and 2% SDS.
RESULTS
Ectodomain Cleavage Site-To obtain N-terminal sequence information regarding the m80 ErbB-4 fragment, a large number of cultures of T47-14 cells were treated with TPA for 30 min, and the m80 fragment was immunopurified by two rounds of antibody precipitation. A single Coomassie Blue-stained 80-kDa band was then eluted and subjected to automated Edman microsequencing. The first seven cycles yielded the sequence STLPQ(R/H)A. The alignment of this sequence with the known sequence of ErbB-4 is presented in Fig. 1 . The sequence obtained for the N terminus of the m80 fragment aligns correctly with the ErbB-4 Jm-a isoform sequence (16) beginning with Ser-652 and is within the receptor stalk region between the second cysteine-rich domain and the transmembrane domain. Also presented in Fig. 1 are sequences for the stalk regions of the Jm-b ErbB-4 isoform, ErbB-1, ErbB-2, and ErbB-3.
The above data indicate that ectodomain cleavage of ErbB-4 probably occurs between His-651 and Ser-652. However, it is possible that cleavage occurs prior to this point in the sequence and that the isolated m80 fragment involves a subsequent loss of N-terminal residues due to secondary proteolytic activity. To test the capacity of TACE to cleave ErbB-4 within the stalk region, a 12-residue peptide (YPWTGHSTLPQH) corresponding to residues 646 -657 of ErbB-4 was incubated with recombinant TACE. Cleavage of the peptide was assessed by mass spectrometry. This approach has been used before with other cell surface molecules that are subject to TACE-mediated ectodomain cleavage. Since the TACE-dependent cleavage site of pro-TNF␣ has been well characterized by this approach (17, 18) , a 12-residue peptide (SPLAQAVRSSSR) including the known cleavage site within stalk region of pro-TNF␣ was used as a control.
The initial experiments utilized reaction conditions that have been reported previously to support the TACE-dependent cleavage of the pro-TNF␣ peptide substrate. The results, shown in Fig. 2A , demonstrate that under these conditions the pro-TNF␣ substrate peptide was cleaved following incubation with TACE and that two major products were detected, peptides a and b. These two peptides correspond to those expected for cleavage of the substrate between Ala-76 and Val-77, the known pro-TNF␣ cleavage site (17, 18) . Under these same
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reaction conditions, however, the ErbB-4 peptide was not cleaved (data not shown).
In view of the above result, the reaction conditions were readjusted to include the addition of more enzyme and a pro- 
shown in Fig. 2B . In the absence of added TACE no degradation products from the ErbB-4 peptide were detected. Under these conditions the presence of TACE did induce the cleavage of the ErbB-4 substrate peptide with the appearance of three peptide products. The peptide products denoted B and A correspond, respectively, to peptides having the sequence YPWTGH and STLPQH. These are the products expected by cleavage of the substrate between His and Ser residues corresponding to residues 651 and 652 of ErbB-4. Also, the sequence of peptide A corresponds to the N-terminal sequence obtained for the isolated m80 ErbB-4 fragment. Under these conditions in vitro a third peptide, denoted C, was also produced and corresponds to the sequence YPWTGHSTLP of the ErbB-4 peptide. This most likely arises from a second cleavage site in the substrate between residues Pro and Gln and would predict the presence of a fourth product, a dipeptide Gln-His, that was not detected in the chromatogram. Most likely this represents an in vitro cleavage that does not occur in vivo.
Role of Tyrosine Kinase Activity in ErbB-4 Ectodomain
Cleavage-A significant question in the ligand-induced proteolytic processing of ErbB-4 is whether its growth factor-dependent tyrosine kinase activity is required. One approach would be to transfect a kinase-negative ErbB-4 mutant into recipient cells and then assay heregulin-induced cleavage. However, we have reported previously that exogenously expressed ErbB-4, in several recipient cell lines, does not exhibit heregulin-induced proteolytic processing (11) . The reasons for this are not clear but preclude a mutagenesis approach.
Several highly selective tyrosine kinase chemical inhibitors have been developed to ErbB-1 and can be used at higher concentrations to inhibit all ErbB tyrosine kinase activities. In the experiment shown in Fig. 3 , PD153035 (19) was used at a concentration experimentally determined to completely prevent heregulin-dependent ErbB-4 tyrosine kinase activity. When T47D cells were treated with heregulin or TPA, formation of the m80 ErbB-4 fragment was increased. When the cells were exposed to PD153035 and heregulin or TPA, the amount of m80 fragment formed was significantly decreased, particularly in the case of heregulin stimulation. Blotting with antiphosphotyrosine shows that heregulin provoked autophosphorylation of ErbB-4, but TPA did not. Similar results also were obtained with a different ErbB kinase inhibitor CI-1003 (20) .
The data show, somewhat surprisingly, that the tyrosine kinase inhibitors abrogate TPA induction of ErbB-4 ectodomain cleavage, although TPA does not induce a detectable level of ErbB-4 tyrosine phosphorylation. In this experiment ErbB-4 cleavage was measured in T47D cells, a breast cancer line in which TPA also induces the shedding of endogenous heregulin from its cell surface precursor. 2 It seems possible, therefore, that this TPA-dependent autocrine circuit contributes to the TPA-induced cleavage of ErbB-4. Although TPA treatment does not produce a detectable level of ErbB-4 autophosphorylation, it is possible that autocrine stimulation occurs at a low level compared with the addition of a saturating quantity of exogenous heregulin. To test the T47-14 cells, an NIH/3T3 fibroblast cell line that expresses exogenous ErbB-4 was treated with TPA in the presence and absence of tyrosine kinase inhibitors. These cells do not express detectable levels of endogenous heregulin. The results, shown in Fig. 4 , demonstrate that in this cell line TPA-induced cleavage was not sensitive to inhibitors of ErbB tyrosine kinase activity.
In a previous study, we reported that ErbB-4 is rapidly translocated to a detergent-insoluble fraction following the addition of heregulin but not TPA (11) . This event correlates with the sensitivity of ErbB-4-expressing cells to ectodomain cleavage initiated by heregulin. Therefore, we tested whether tyrosine kinase activity is necessary for heregulin-dependent translocation of ErbB-4 to the detergent-insoluble fraction in T47D cells. The results of this experiment, shown in Fig. 5A , demonstrate that tyrosine kinase activity is required for this translocation.
To pursue the correlation between ectodomain cleavage of ErbB-4 and translocation to the detergent-insoluble fraction, we have measured the level of TACE found in the detergentsoluble and -insoluble fractions. The data, presented in Fig. 5B , indicate that significantly higher levels of TACE are present in the detergent-insoluble fraction compared with the soluble fraction. Although heregulin is required for ErbB-4 translocation to the insoluble fraction, the growth factor has only a small influence on the distribution of TACE. The addition of heregulin slightly increased (43%) the level of TACE in the detergentsoluble fraction and slightly decreased (30%) the amount of TACE in the insoluble fraction.
Association of m80 and ErbB-2-A characteristic of ErbB receptors is their propensity to homo-and heterodimerize fol- lowing the addition of ligand. ErbB-4 can homodimerize or heterodimerize with ErbB-2 (1). The mechanism of ErbB-4 association with itself or ErbB-2 is not known.
To test whether the m80 ErbB-4 fragment associates with the full-length ErbB-4 molecule, T47D cells were treated with heregulin or TPA, and lysates were prepared. One-half of each lysate was then incubated with an ErbB-4 antibody that recognizes an ectodomain epitope not present in the m80 fragment to selectively precipitate the full-length ErbB-4 molecule. The immunoprecipitates were then tested by Western blotting for ErbB-4-reactive material using an antibody to a C-terminal epitope present in both the full-length and m80 forms of ErbB-4. The results, shown in Fig. 6 (lanes 1-3) , indicate that no m80 fragment could be detected. Although the level of fulllength molecule is decreased by TPA or heregulin treatment, there is still a reasonable level available to potentially form an association complex with the m80 fragment. The remaining one-half of each lysate was used as a positive control. ErbB-4 was immunoprecipitated with an antibody to the ErbB-4 C terminus and then blotted with the same antibody. The results (Fig. 6, lanes 4 -6) show that in this experiment the m80 fragment was, in fact, generated by heregulin or TPA.
To assess the possible association of the ErbB-4 m80 fragment with ErbB-2, the experiment shown in Fig. 7 was conducted. T47D cells were treated with either heregulin (Fig. 7A) or TPA (Fig. 7B) in the presence or absence of ALLN, a protease inhibitor, which we have shown previously prevents the metabolic degradation of the m80 ErbB-4 fragment (10). After treating the cells, lysates were prepared and precipitated with an antibody to ErbB-2. The precipitates were subsequently analyzed by Western blotting with antibody to the C terminus of ErbB-4. The results show that following the addition of either heregulin or TPA to induce ErbB-4 ectodomain cleavage, the m80 fragment is found associated with ErbB-2, which is not cleaved. The presence of ALLN increases both the basal and agonist-stimulated levels of the m80 fragment associated with ErbB-2.
In these experiments, the data from untreated cells (lane 1 in Fig. 7, A and B) show that ErbB-2 coprecipitates with ErbB-4 and implies the presence of preformed dimers or oligomers. Others have shown that the ErbB-1 receptor can self-associate in the absence of added ligand (21) (22) (23) (24) (25) . To date attempts to show by cross-linking reagents whether this association of ErbB-2 and ErbB-4 represents preformed dimers have not been repeatedly successful, most probably due to the limited level of for 1 h prior to the addition of heregulin (40 ng/ml) or TPA (300 ng/ml) as indicated. After an additional 30 min of incubation, lysates were prepared. One-half of each lysate was subjected to precipitation of ErbB-4 using either a N-terminal epitope antibody (lanes 1-3) or a C-terminal epitope antibody (lanes 4 -6) . After SDS-PAGE, all samples were blotted with an antibody to an ErbB-4 C-terminal epitope. IP, immunoprecipitation.
FIG. 7.
Association of the m80 ErbB-4 fragment with ErbB-2. T47D cells were pretreated, as indicated, with ALLN (250 M) for 1 h prior to the addition of heregulin (40 ng/ml) (A) or TPA (300 ng/ml) (B). After an additional 30 min of incubation, cell lysates were prepared. The lysates were analyzed by precipitation with an antibody to ErbB-2 and blotting with an antibody to ErbB-4 (C-terminal epitope). Subsequently, the blots were stripped and reblotted with antibody to ErbB-2. IP, immunoprecipitation.
ErbB-4 Ectodomain Cleavage
ErbB-4 expression in T47D cells and the low efficiency of chemical cross-linkers. DISCUSSION The mechanism by which ADAMs recognize and cleave transmembrane substrates is not known (26, 27) . The cleavage sites in a variety of substrates are located within the ectodomain stalk region ϳ2-20 residues from the transmembrane domain, and no consensus cleavage site has been identified to predict residues involved in ADAM-mediated cleavage. The data in this article identify the ErbB-4 cleavage site as between residues His-651 and Ser-652. This places the cleavage site between the 8th and 9th residues outside the transmembrane domain of ErbB-4. Identification of this as the cleavage site is consistent with in vivo cleavage data identifying Ser-652 as the N-terminal residue of the m80 fragment and in vitro data demonstrating TACE-dependent cleavage of an ErbB-4 peptide between His-651 and Ser-652. These are the approaches that have generally been employed to identify ADAM cleavage sites, and in most all cases the in vivo and in vitro data do not conflict (28) .
Significantly, higher concentrations of TACE were required for cleavage of the ErbB-4 peptide than for cleavage of the pro-TNF␣ peptide. This is not unexpected as many substrates are cleaved inefficiently by TACE when compared with cleavage of the pro-TNF␣ peptide (29 -32) . When quantitation has been possible, the difference, measured by k cat /K m values, is ϳ10 2 to 10 3 . Also, secondary cleavages in vitro have sometimes been noted (32) , similar to what we detected (peptide C) with the ErbB-4 peptide. The underlying reason for the relatively inefficient cleavage in vitro of some peptides by TACE is not understood. In the case of L-selectin cleavage by TACE, evidence has been presented that the enzyme-substrate recognition event in vivo involves regions of the substrate distal to the cleavage site region (33) . This may be the case for ErbB-4 also and would explain the relatively inefficient cleavage of the 12-residue peptide in vitro.
ADAM cleavage sites lie within what is described as the ectodomain "stalk" or "stem" region of their transmembrane substrates (26, 27) . This is the region between the transmembrane domain and globular folding in the ectodomain. ErbB receptors have two cysteine-rich regions, the second of which is just before the stalk region. In Fig. 1 the final cysteine residue in the ectodomain sequence is somewhat arbitrarily defined as one border of the stalk region, whereas the first residue of the transmembrane domain is taken as the other border. On this basis ErbB-4 has a stalk region of 16 residues, and the ectodomain cleavage site is almost in the middle of this region. When other ErbB receptor stalk regions and that of the non-cleavable Jm-b isoform of ErbB-4 are similarly aligned, each has a significantly shorter stalk region of 9 to 6 residues, and in no instance has ADAM-dependent cleavage been observed at a significant level (9) . That stalk length may be an important factor that limits ADAM cleavage of substrates is illustrated by the L-and E-selectins (34, 35) . L-selectin has a long stalk (15 residues) and is cleaved, whereas E-selectin has a shorter stalk (7 residues) and is not cleaved. Deletions in the L-selectin stalk abrogate its sensitivity to cleavage.
ErbB-4 cleavage can be initiated by TPA or by heregulin, and differences in the mechanisms have been noted (11) . In particular, heregulin-dependent cleavage seems to correlate with translocation to a detergent-insoluble, perhaps internal, compartment, but TPA-dependent cleavage does not. Data presented herein show that tyrosine kinase inhibitors prevent heregulin-dependent translocation to the detergent-insoluble fraction and also prevent heregulin-dependent ectodomain cleavage. In contrast, tyrosine kinase activity is not required for TPA-dependent ectodomain cleavage of ErbB-4. We suggest that ErbB-4 trafficking to an internalization pathway is required for growth factor-dependent cleavage and that this explains, at least in part, the requirement for tyrosine kinase activity. ErbB-1 trafficking to the endocytic pathway following the addition of growth factor requires activation of its tyrosine kinase (36) .
ErbB-4 is known to homodimerize or to heterodimerize with other ErbB receptors, especially ErbB-2 (1). Therefore, we used co-precipitation assays to assess the possible interaction of the ErbB-4 m80 fragment with intact ErbB molecules. The data show that this fragment is not detected in association with full-length ErbB-4 but is readily detected in association with full-length ErbB-2. This raises two questions. By what means does such a novel heteroassociation take place, and is this complex related to ectodomain cleavage either as a substrate or a product?
Within the ErbB receptor family there is significant data that dimer formation, particularly homodimers, depends on ectodomain conformational changes provoked by ligand binding (37) . There are also data to suggest that heterologous associations between ErbB family members can be mediated, at least in part, by cytoplasmic domain sequences (38 -41) . This includes ErbB-2 and ErbB-4. It seems that the m80 association with ErbB-2 is probably an example of cytoplasmic domainmediated association. The data in this article do not permit a distinction between an m80 ErbB-4/ErbB-2 dimer or a higher order association complex.
Interestingly, we have reported previously that following the addition of heregulin, both ErbB-4 (11) and ErbB-2 (42) translocate to a detergent-insoluble fraction. It is not known how this event relates to ectodomain cleavage, but data herein show that this fraction does contain high levels of TACE. The m80 ErbB-4 fragment is not found in the detergent-insoluble fraction (11) , but this does not indicate in which fraction this fragment is actually produced. Some cells that express ErbB-4 do not exhibit heregulin-dependent ectodomain cleavage, although TPA-dependent cleavage does take place. In those cells, ErbB-4 is not translocated to the detergent-insoluble fraction but is tyrosine-phosphorylated following heregulin addition. Therefore, based on all these observations it is possible that heregulin induces the association of ErbB-4 and ErbB-2 and their translocation, perhaps as a complex, to a TACE-enriched detergent-insoluble fraction where ectodomain cleavage is initiated. Interestingly, evidence has been presented that ectodomain cleavage of APP, by an ADAM ␣-secretase activity or ␤-secretase activity (an aspartyl protease), takes place in detergent-insoluble domains, characterized as rafts or caveolae (43) (44) (45) (46) (47) (48) . Similarly, L-selectin ectodomain cleavage is associated with detergent-resistant rafts (49) . Evidence has been reported to indicate that dimerization of APP increases its sensitivity to ectodomain cleavage (50) . However, we cannot rule out the possibility that the observed association between the ErbB-4 m80 fragment and ErbB-2 occurs after ectodomain cleavage of ErbB-4 has occurred. Also, these results do not preclude the participation of ErbB-4 homodimers in the cleavage event.
